Clinical Trial OutcomesEfficacy in the higher dose of larsucosterol was numerically weaker than the lower dose, raising concerns about the drug's performance.
Drug EfficacyLarsucosterol did not reach statistical significance for either dose in both the primary and key secondary endpoints in the Phase 2b AHFIRM study.
Investment OutlookWith larsucosterol missing the primary and key secondary efficacy endpoints, analysts maintain a Neutral stance on DRRX shares, awaiting further regulatory guidance.